Ron Korn, MD, PhD
Chief Medical Officer
Dr. Korn is an internationally recognized expert in Cancer Imaging. A scientist at his core, he completed a PhD in Molecular Biology at Albert Einstein College of Medicine, his Medical Degree from Stanford School of Medicine and Residency and Fellowship training in Diagnostic Radiology and Nuclear Medicine from University of Pennsylvania. Dr. Korn has specialized in PET imaging, Radiopharmaceutical development and Cancer Biology for over 20 years with extensive involvement in clinical research leading to several high-profile publications in major peer review journals. His work has resulted in the approval of several cancer drugs based upon PET imaging …
Robert E. Reiter, MD
Co-Founder of ImaginAb, Consultant
Dr. Reiter is a Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at UCLA. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a 12 million dollar research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. As co-developer of ImaginAb’s technology and Chief Medical Advisor, Dr. Reiter helps ensure high clinical impact and relevance by guiding the validation studies for ImaginAb’s clinical imaging pipeline. Dr. Reiter is a prominent figure …
Brian Abeysekera, PhD
Dr. Brian Abeysekera, has more than 25 years of experience in radioisotope and radiopharmaceutical development, including production, radiochemistry, quality control, quality assurance and regulatory affairs activities in the United States and Canada. He is President of PharmaSPECT Inc, a company that provides cGMP and Manufacturing, Quality and Regulatory expertise to Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) radiopharmaceutical manufacturers. He previously served as Vice President, Manufacturing, Molecular Insight Pharmaceuticals …
Alex Gibson, PhD
Dr Alex Gibson has over 20 years’ of experience working in the Radiopharmaceutical industry primarily at GE Healthcare where he held several roles within R&D but most latterly as Head of Research Alliances. Within that position he had responsibility to build and maintain a wide variety of key partnerships. He has wide experience of creating innovative collaborative models with Pharma companies and academic institutions alike across a range of disease areas in different phases of research and development. Currently he works with several small diagnostic companies in developing and maintaining …
We have retained the consulting services of Jerry Liebrand, Liebrand Consulting LLC to provide strategic direction for PSMA. Jerry served as Vice President, Product Acquisitions & Licensing for GE Healthcare. With more than 25 years in the healthcare industry, he has worked for leading companies including Sanofi Winthrop Pharmaceuticals, Nycomed AS, and Amersham plc.
Consultant, Global IP Asset Management
Thomas is a US/Canadian intellectual property (IP) and transaction attorney with 22+ years’ experience in Global IP Asset Management. He provides worldwide strategic advice for IP portfolio assets to achieve licensing, M&A and commercialization objectives. From 2005-2016, Thomas was a member of the legal/IP department at Novartis (Cambridge, MA and Basel, Switzerland).